日本の前臨床CRO市場レポート：サービス、最終用途、地域別、2025年～2033年

日本の前臨床CRO市場の市場規模は2024年に2億4,320万米ドルに達しました。IMARC Groupは、2025年から2033年にかけての成長率（CAGR）は8.3％で、2033年には5億3,990万米ドルに達すると予測しています。同市場は、各社が自社の中核となる強みを重視し、特殊治療における最近の画期的な進歩を背景に、大きな勢いを見せています。

本レポートで扱う主な質問

• 日本の前臨床CRO市場はこれまでどのように推移し、今後どのように推移するのか？
• 日本の前臨床CRO市場へのCOVID-19の影響は？
• 日本の前臨床CRO市場のサービス別の内訳は？
• 日本の前臨床CRO市場の最終用途別の内訳は？
• 日本の前臨床CRO市場のバリューチェーンにはどのような段階がありますか？
• 日本の前臨床CROにおける主な促進要因と課題は何か？
• 日本の前臨床CRO市場の構造と主要プレイヤーは？
• 日本の前臨床CRO市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本の前臨床CRO市場：イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本の前臨床CRO市場情勢

• 過去および現在の市場動向（2019年～2024年）
• 市場予測（2025-2033）

第6章 日本の前臨床CRO市場：サービス別の内訳

• バイオ分析とDMPK研究
• 毒性試験
• その他

第7章 日本の前臨床CRO市場：最終用途別の内訳

• バイオ医薬品企業
• 政府機関および学術機関
• 医療機器企業

第8章 日本の前臨床CRO市場：競合情勢

• 概要
• 市場構造
• 市場プレーヤーのポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第9章 主要企業のプロファイル

第10章 日本の前臨床CRO市場：業界分析

• 促進要因・抑制要因・機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第11章 付録

Japan preclinical CRO market size reached USD 243.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 539.9 Million by 2033, exhibiting a growth rate (CAGR) of 8.3% during 2025-2033. The market is witnessing significant momentum due to a heightened emphasis among companies on their core strengths and recent breakthroughs in specialized treatments.

A preclinical contract research organization (CRO) is a company that delivers diverse research and development (R&D) services to the biotechnology, pharmaceutical, and medical device sectors. These services encompass a wide spectrum, including toxicology investigations, pharmacokinetic assessments, formulation development, regulatory assistance, and pharmacodynamic studies. The applications of preclinical CRO services span various domains, encompassing drug discovery, medical device evaluation, biocompatibility assessments, disease modeling, safety pharmacology investigations, and the selection of appropriate dosage forms. These services facilitate the acceleration of product development, bolster compliance with regulatory requirements, tap into specialized expertise, optimize resource allocation, and offer flexible research solutions.

Japan Preclinical CRO Market Trends:

In the context of the Japanese market, there is an increasing emphasis among companies on concentrating their efforts on their core competencies. This trend is driving the demand for preclinical contract research organizations (CROs) as they enable companies to delegate specialized preclinical tasks, allowing them to allocate more resources to their primary areas of focus, such as late-phase clinical trials or marketing endeavors. Moreover, the surging demand for preclinical CRO services in Japan is linked to the rapid expansion of the pharmaceutical sector in emerging economies, driven by the need to address unique healthcare challenges and cater to a growing patient population. Additionally, the market is benefiting from recent advancements in specialized treatments like personalized medicine, biologics, and gene therapies, which necessitate precise and nuanced preclinical testing. Furthermore, the widespread adoption of preclinical CROs is driven by the desire to adopt a risk-balanced approach, especially in light of the high failure rate in drug development. Lastly, the introduction of cutting-edge technologies that play a pivotal role in the successful execution of preclinical studies is expected to bolster the market's growth prospects in Japan over the forecasted period.

Japan Preclinical CRO Market Segmentation:

Service Insights:

• Bioanalysis and DMPK Studies
• Toxicology Testing
• Others

End Use Insights:

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan preclinical CRO market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan preclinical CRO market?
• What is the breakup of the Japan preclinical CRO market on the basis of service?
• What is the breakup of the Japan preclinical CRO market on the basis of end use?
• What are the various stages in the value chain of the Japan preclinical CRO market?
• What are the key driving factors and challenges in the Japan preclinical CRO?
• What is the structure of the Japan preclinical CRO market and who are the key players?
• What is the degree of competition in the Japan preclinical CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Preclinical CRO Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Preclinical CRO Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Preclinical CRO Market - Breakup by Service

• 6.1 Bioanalysis and DMPK Studies
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Toxicology Testing
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 Others
  • 6.3.1 Historical and Current Market Trends (2019-2024)
  • 6.3.2 Market Forecast (2025-2033)

7 Japan Preclinical CRO Market - Breakup by End Use

• 7.1 Biopharmaceutical Companies
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Government and Academic Institutes
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Medical Device Companies
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)

8 Japan Preclinical CRO Market - Competitive Landscape

• 8.1 Overview
• 8.2 Market Structure
• 8.3 Market Player Positioning
• 8.4 Top Winning Strategies
• 8.5 Competitive Dashboard
• 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

• 9.1 Company A
  • 9.1.1 Business Overview
  • 9.1.2 Product Portfolio
  • 9.1.3 Business Strategies
  • 9.1.4 SWOT Analysis
  • 9.1.5 Major News and Events
• 9.2 Company B
  • 9.2.1 Business Overview
  • 9.2.2 Product Portfolio
  • 9.2.3 Business Strategies
  • 9.2.4 SWOT Analysis
  • 9.2.5 Major News and Events
• 9.3 Company C
  • 9.3.1 Business Overview
  • 9.3.2 Product Portfolio
  • 9.3.3 Business Strategies
  • 9.3.4 SWOT Analysis
  • 9.3.5 Major News and Events
• 9.4 Company D
  • 9.4.1 Business Overview
  • 9.4.2 Product Portfolio
  • 9.4.3 Business Strategies
  • 9.4.4 SWOT Analysis
  • 9.4.5 Major News and Events
• 9.5 Company E
  • 9.5.1 Business Overview
  • 9.5.2 Product Portfolio
  • 9.5.3 Business Strategies
  • 9.5.4 SWOT Analysis
  • 9.5.5 Major News and Events

10 Japan Preclinical CRO Market - Industry Analysis

• 10.1 Drivers, Restraints, and Opportunities
  • 10.1.1 Overview
  • 10.1.2 Drivers
  • 10.1.3 Restraints
  • 10.1.4 Opportunities
• 10.2 Porters Five Forces Analysis
  • 10.2.1 Overview
  • 10.2.2 Bargaining Power of Buyers
  • 10.2.3 Bargaining Power of Suppliers
  • 10.2.4 Degree of Competition
  • 10.2.5 Threat of New Entrants
  • 10.2.6 Threat of Substitutes
• 10.3 Value Chain Analysis

11 Appendix